HEMATOLOGY

Harry Erba, MD, PhD, provided his insights into the groundbreaking myeloMATCH trial and its influence on the treatment of acute myeloid leukemia and myelodysplastic syndromes.

The investigational new drug application for UB-VV111, potentially the first in situ generated CD19 CAR T-cell therapy, has been cleared by the FDA, and a phase 1 trial in hematologic malignancies will begin.

Harry Erba, MD, PhD, discusses myeloMATCH, a precision medicine umbrella trial for patients with acute myeloid leukemia or myelodysplastic syndrome.

The FDA has extended the PDUFA target action date for the new drug application of revumenib for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia to December 26, 2024.

The NCCN has updated its guidelines to recommend imetelstat as a top treatment for symptomatic anemia in lower-risk MDS, following its FDA approval based on encouraging phase 3 trial results.

Guillermo Garcia-Manero, MD, provides advice to community oncologists on the treatment of anemia for patients with lower-risk MDS.

An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.

A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.

Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.

Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.

A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.

Guillermo Garcia-Manero, MD, reviews recent results from the COMMANDS study investigating luspatercept versus epoetin alfa in patients with ESA-naïve, transfusion dependent LR-MDS.

An expert on the treatment of lower-risk MDS outlines practices for identifying patients who are suitable to receive erythroid maturating agents for treatment of anemia.

A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.

The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.

During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.

Neel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.

The FDA has accepted the resubmitted application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants.

Corey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.

The FDA has granted a rare pediatric disease designation to SLS009 for treating pediatric acute myeloid leukemia.

Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Elias Jabbour, MD, provides an overview of the significance of the FDA approval of ponatinib plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The FDA granted a fast track designation to DSP-5336 in relapsed/refractory AML with a KMT2A rearrangement or NPM1 mutation, showing promising results and safety in early trials.

Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.

A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.

The completion of the End of Phase 2 meeting for the phase 1B/2 trial of annamycin and cytarabine in acute myeloid leukemia has been announced.

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

Hannah Choe, MD, provides insights on potential areas for improvement in developing more targeted and effective treatments for chronic GVHD.

Corey Cutler, MD, MPH, discusses how axatilimab’s mechanism of action differs from currently available therapies for patients with chronic GVHD.

A phase 1/2 trial evaluating DSP-5336 for the treatment of patients with acute leukemia harboring either an NPM1 mutation or KMT2A rearrangement showed early response rates.